Anastrozole vs Masteron

FDA Approved vs Moderate Research
compatible Researched · 90% Masteron's inherent anti-estrogenic properties often reduce or eliminate the need for anastrozole when running moderate testosterone doses. If both are used, estradiol should be monitored carefully to avoid over-suppression, which can impair joint comfort, lipid health, and bone mineral density. Many users find that adding Masteron to a testosterone cycle allows them to drop their AI entirely or reduce the dose significantly.

Molecular Data

Anastrozole Masteron
Weight 293.37 Da 304.47 Da (base)
Half-life ~40-50 hours ~2 days (propionate), ~10 days (enanthate)
Type Nonsteroidal aromatase inhibitor (triazole derivative) DHT-derived anabolic steroid (C20H32O2)

Key Benefits

Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
Masteron
01 Produces a hard, dry, and grainy appearance by eliminating subcutaneous water retention
02 Mild anti-estrogenic properties that can reduce or replace the need for aromatase inhibitors on cycle
03 Does not aromatize, eliminating estrogen-mediated side effects from the compound itself
04 Enhances the visual effects of other steroids in a stack by reducing water retention and bloat
05 Modest increases in strength without significant weight gain, useful for weight-class athletes
06 Improves muscle density and vascularity at low body fat percentages
07 Well-tolerated with a relatively mild side effect profile compared to other anabolic steroids
08 Short detection window with propionate ester compared to many other injectable steroids

Dosing Protocols

Anastrozole
0.25-0.5mg EOD or E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
Masteron
300-500 mg/week / Every other day (propionate) or 2x per week (enanthate)
Cutting / Aesthetic Enhancement 300-400 mg/week Every other day (propionate) or 2x per week (enanthate)
Contest Preparation 400-500 mg/week Every other day or daily (propionate)
AI Replacement / Estrogen Management 200-300 mg/week Every other day (propionate) or 2x per week (enanthate)

Side Effects

Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
Masteron
Hair loss and accelerated male pattern baldness (significant risk as a DHT derivative - the most commonly reported side effect)
Acne and increased skin oiliness, particularly on the back and shoulders
Suppression of natural testosterone production (requires PCT or ongoing TRT)
Injection site pain or discomfort (more common with propionate ester)
Mild aggression or irritability from elevated androgenic activity
HDL cholesterol suppression and adverse lipid profile changes
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Pregnancy or potential for pregnancy (causes virilization of female fetus)
Known hypersensitivity to drostanolone or any formulation components
Severe hepatic impairment
Pre-existing significant hair loss where further androgenic exposure is unacceptable
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled cardiovascular disease or severe dyslipidemia

Research Evidence

Anastrozole Masteron
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest March 2020
FDA Approved Yes No

This comparison is for educational and research purposes only. Consult a healthcare professional before use.